Two receptors, one peptide, and the geometry of fat loss.

For two decades, the prevailing wisdom in incretin pharmacology held that GIP — glucose-dependent insulinotropic polypeptide — was the lesser sibling. GLP-1 got the headlines and the FDA approvals. GIP, despite being the first incretin discovered, was considered metabolically ambiguous: it stimulated insulin in healthy people but appeared to lose efficacy in type 2 diabetes, and chronic GIP receptor activation in mice seemed to promote rather than oppose fat storage.

Tirzepatide was designed against that consensus.

In 2016, medicinal chemists at Eli Lilly's Indianapolis facility, working from a scaffold modeled on native GIP, asked a contrarian question. What if GIP receptor agonism, when delivered together with GLP-1 agonism in the same molecule, did something neither receptor could do alone? The hypothesis was that the two pathways would not simply add — they would interact.

Origin

The lead candidate, originally coded LY3298176, was a 39-amino-acid linear peptide engineered with a C20 fatty-diacid tail anchored at lysine 20 — a longer hydrophobic anchor than semaglutide's C18. The longer tail provided albumin binding strong enough to support once-weekly dosing. The amino-acid sequence borrowed from GIP at the N-terminus, hybridized through the middle, and ended in a tail that activates both receptors at full agonist potency.

The molecule is biased — meaning it activates GLP-1 receptor signaling somewhat differently than native GLP-1 does. Specifically, it favors cAMP signaling over beta-arrestin recruitment. Whether that bias is the source of the unusual effect size or simply a chemical accident remains debated.

Mechanism

An analogy helps. If GLP-1 receptor activation is one ratchet on a metabolic winch — pulling appetite down, slowing gastric emptying, augmenting insulin release — then GIP receptor activation is a second ratchet positioned on a slightly different gear. Each one alone moves weight. Both together move it further than either could alone, and not because of simple addition.

GIP appears to do something interesting in adipose tissue. Acute GIP receptor activation increases lipolysis — the release of fatty acids from fat stores — and may also increase fatty-acid re-esterification. The net effect is a higher metabolic flux through fat tissue rather than simple storage. When that effect is paired with GLP-1's appetite suppression and insulin augmentation, the result is a body in net negative energy balance with disproportionately preserved lean mass.

Investigators at the University of Leicester have published mechanism reviews proposing that GIP receptor agonism may also reduce nausea by acting on antiemetic centers — partially canceling out GLP-1's emetic signal. This may explain why tirzepatide tolerability profiles, despite the larger weight loss, are not proportionally worse than semaglutide's.

What the latest research shows

SURMOUNT-1, published in NEJM in 2022, established the headline number: 20.9 percent mean weight reduction at 72 weeks on the 15mg dose, in 2,539 adults with obesity and without diabetes. The effect-size distribution was bimodal at the high end — about a third of participants lost more than 25 percent of body weight. No prior pharmacological agent in this disease category had approached that figure.

What followed in 2024 was a string of trials extending the molecule into territories the metabolic literature had not seriously expected.

SUMMIT, published in NEJM in November 2024 and led from Baylor and Imperial College London, randomized 731 patients with heart failure with preserved ejection fraction and obesity. Tirzepatide reduced the composite of cardiovascular death and worsening heart failure by 38 percent over a median follow-up of 104 weeks. The CMR substudy, led by Christopher Kramer at the University of Virginia, showed something more unusual: a measurable reduction in left-ventricular mass and a decrease in paracardiac adipose tissue.

SURMOUNT-OSA, published in the same month, enrolled 469 adults with obesity and moderate-to-severe obstructive sleep apnea at sites including the Charité University Hospital in Berlin and the Woolcock Institute at Macquarie University in Sydney. After 52 weeks of tirzepatide, the apnea-hypopnea index fell by 25 events per hour in the cohort using continuous positive airway pressure and 29 events per hour in the cohort that was not. A 2024 follow-up analysis from the University of Turin estimated that 51 percent of participants achieved disease resolution.

On the hepatology side, SYNERGY-NASH (NEJM 2024) showed steatohepatitis resolution in 44 to 62 percent of patients with biopsy-proven MASH and stage 2 or 3 fibrosis after 52 weeks. Pathology was adjudicated by collaborators at Yokohama City University in Japan, the University of Turin in Italy, and Angers University Hospital in France.

Beyond the obvious

The most provocative recent work comes from a laboratory at Northwest Normal University in Lanzhou, China. Yang and colleagues administered tirzepatide intraperitoneally to APP/PS1 transgenic mice — a standard murine model of Alzheimer's pathology — for eight weeks. Amyloid plaque burden in the cortex decreased. GFAP expression, a marker of reactive astrogliosis, fell. Mitochondrial membrane potential and reactive oxygen species production normalized in cortical astrocytes. The mechanism appeared to involve restoration of brain glucose metabolism — specifically, upregulation of GLUT1, hexokinase, and phosphofructokinase — through GLP-1 receptor activation in glial cells.

A 2025 review by Alshehri and colleagues at Princess Nourah bint Abdulrahman University in Riyadh, with collaborators at Mustansiriyah University in Baghdad, Damanhour University in Egypt, and the University of Witten-Herdecke in Germany, synthesized the case for tirzepatide as a candidate for Alzheimer's clinical investigation.

A separate line of work at the University of Cambridge has examined tirzepatide effects on bone — a concern with rapid weight loss in older adults. The early signal suggests GIP receptor agonism may partially preserve trabecular bone density, an effect that pure GLP-1 agonism does not produce.

Often studied alongside

Recent investigations have paired tirzepatide with Retatrutide in protocols designed to dissect the additive contribution of glucagon receptor agonism on top of dual GIP/GLP-1 activation. Adjacent research has also examined tirzepatide alongside MOTS-c when investigating mitochondrial-pathway redundancy in metabolic syndrome models.

Practical considerations

Tirzepatide's pharmacokinetic half-life is approximately 116 hours — slightly shorter than semaglutide's, but sufficient for once-weekly subcutaneous dosing. Reconstituted material is stable at refrigeration for 21 days in laboratory protocols. The standard titration schedule begins at 2.5mg weekly and escalates at four-week intervals to a maximum of 15mg, calibrated to manage gastrointestinal tolerability. None of this is medical advice — Precursor's compounds are research-use-only and not for human consumption.